• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ICON plc

    5/15/25 7:12:06 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ICON PLC

    (Name of Issuer)


    Ordinary Shares, par value Euro 0.06 each

    (Title of Class of Securities)


    G4705A100

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G4705A100


    1Names of Reporting Persons

    Artisan Partners Asset Management Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,121,885.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,290,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,290,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  (g) Artisan Partners Holdings LP is the sole limited partner of Artisan Partners Limited Partnership and the sole member of Artisan Investments GP LLC; Artisan Investments GP LLC is the general partner of Artisan Partners Limited Partnership; Artisan Partners Asset Management Inc. is the general partner of Artisan Partners Holdings LP.


    SCHEDULE 13G

    CUSIP No.
    G4705A100


    1Names of Reporting Persons

    Artisan Partners Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,121,885.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,290,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,290,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  (g) Artisan Partners Holdings LP is the sole limited partner of Artisan Partners Limited Partnership and the sole member of Artisan Investments GP LLC; Artisan Investments GP LLC is the general partner of Artisan Partners Limited Partnership; Artisan Partners Asset Management Inc. is the general partner of Artisan Partners Holdings LP.


    SCHEDULE 13G

    CUSIP No.
    G4705A100


    1Names of Reporting Persons

    Artisan Investments GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,121,885.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,290,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,290,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  (g) Artisan Partners Holdings LP is the sole limited partner of Artisan Partners Limited Partnership and the sole member of Artisan Investments GP LLC; Artisan Investments GP LLC is the general partner of Artisan Partners Limited Partnership; Artisan Partners Asset Management Inc. is the general partner of Artisan Partners Holdings LP.


    SCHEDULE 13G

    CUSIP No.
    G4705A100


    1Names of Reporting Persons

    Artisan Partners Limited Partnership
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,121,885.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,290,924.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,290,924.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  (g) Artisan Partners Holdings LP is the sole limited partner of Artisan Partners Limited Partnership and the sole member of Artisan Investments GP LLC; Artisan Investments GP LLC is the general partner of Artisan Partners Limited Partnership; Artisan Partners Asset Management Inc. is the general partner of Artisan Partners Holdings LP. (e) Artisan Partners Limited Partnership is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ICON PLC
    (b)Address of issuer's principal executive offices:

    South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
    Item 2. 
    (a)Name of person filing:

    Artisan Partners Asset Management Inc. ("APAM") Artisan Partners Holdings LP ("Artisan Holdings") Artisan Investments GP LLC ("Artisan Investments") Artisan Partners Limited Partnership ("APLP")
    (b)Address or principal business office or, if none, residence:

    APAM, Artisan Holdings, Artisan Investments, and APLP are all located at: 875 East Wisconsin Avenue, Suite 800 Milwaukee, WI 53202
    (c)Citizenship:

    APAM is a Delaware corporation; Artisan Holdings is a Delaware limited partnership; Artisan Investments is a Delaware limited liability company; APLP is a Delaware limited partnership
    (d)Title of class of securities:

    Ordinary Shares, par value Euro 0.06 each
    (e)CUSIP No.:

    G4705A100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,290,924
    (b)Percent of class:

    5.3% (based on 80,756,860 shares outstanding as of 12/31/2024)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    None

     (ii) Shared power to vote or to direct the vote:

    4,121,885

     (iii) Sole power to dispose or to direct the disposition of:

    None

     (iv) Shared power to dispose or to direct the disposition of:

    4,290,924

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The shares reported herein have been acquired on behalf of discretionary clients of APLP. Persons other than APLP are entitled to receive all dividends from, and proceeds from the sale of, those shares. None of those persons, to the knowledge of APAM, Artisan Holdings, Artisan Investments, or APLP has an economic interest in more than 5% of the class.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Artisan Partners Asset Management Inc.
     
    Signature:/s/ Gregory K. Ramirez
    Name/Title:Gregory K. Ramirez, Executive Vice President
    Date:05/15/2025
     
    Artisan Partners Holdings LP
     
    Signature:/s/ Gregory K. Ramirez
    Name/Title:Gregory K. Ramirez, Vice President
    Date:05/15/2025
     
    Artisan Investments GP LLC
     
    Signature:/s/ Gregory K. Ramirez
    Name/Title:Gregory K. Ramirez, Vice President
    Date:05/15/2025
     
    Artisan Partners Limited Partnership
     
    Signature:/s/ Gregory K. Ramirez
    Name/Title:Gregory K. Ramirez, Vice President
    Date:05/15/2025

    Comments accompanying signature:  Exhibit Index Exhibit 1 - Joint Filing Agreement dated 5/15/2025 by and among Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC, and Artisan Partners Limited Partnership.
    Get the next $ICLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    4/29/2025$150.00Overweight → Neutral
    Analyst
    4/14/2025$157.00Buy → Hold
    TD Cowen
    4/10/2025$165.00Overweight → Equal Weight
    Barclays
    3/21/2025$250.00 → $200.00Buy → Neutral
    Goldman
    1/7/2025$263.00Outperform
    RBC Capital Mkts
    10/24/2024$340.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Neutral
    Redburn Atlantic
    9/18/2024$379.00Outperform
    Leerink Partners
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICON plc downgraded by Analyst with a new price target

      Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00

      4/29/25 8:06:12 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by TD Cowen with a new price target

      TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00

      4/14/25 8:13:29 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by Barclays with a new price target

      Barclays downgraded ICON plc from Overweight to Equal Weight and set a new price target of $165.00

      4/10/25 8:49:19 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ICON plc

      SC 13G/A - ICON PLC (0001060955) (Subject)

      11/12/24 11:54:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      2/9/24 11:49:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      1/30/24 12:11:57 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Financials

    Live finance-specific insights

    See more
    • ICON Reports First Quarter 2025 Results

      Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20

      4/30/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc Schedules First Quarter 2025 Earnings Conference Call

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, April 30, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 1, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading

      3/31/25 6:30:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Reports Fourth Quarter and Full Year 2024 Results

      Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing backlog of $24.7 billion, an increase of 1.4% on quarter three 2024 and 8.3% on quarter four 2023. Quarter four revenue of $2,041.1 million, representing a decrease of 1.2% on prior year revenue. Full year revenue of $8,282 million representing a year on year increase of 2.0%. Quarter four adjusted EBITDA of $422.6 million or 20.7% of revenue, an increase of 0.9% on quarter three 2024. Full year adjusted EBITDA of $1,735.8 million or 21.0% of revenue, representing a year on year increase of 2.5%.

      2/19/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% o

      5/7/25 7:27:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Reports First Quarter 2025 Results

      Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20

      4/30/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ICLR
    Leadership Updates

    Live Leadership Updates

    See more
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ICON Announces Appointment of Chief Operating Officer

      ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to

      12/18/24 7:00:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Announces Appointment of New Chief Financial Officer

      ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes

      8/14/24 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by ICON plc

      SCHEDULE 13G - ICON PLC (0001060955) (Subject)

      5/15/25 7:12:06 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by ICON plc

      144 - ICON PLC (0001060955) (Subject)

      5/6/25 5:00:40 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      5/2/25 4:16:26 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care